Silexion Therapeutics Corp SEC Filings

Silexion Therapeutics Corp (SLXN) filed its quarterly report detailing continued operating losses and new financing capacity. For the nine months ended September 30, 2025, the company reported a net loss of $7.5 million on operating expenses of $7.2 million. Cash and cash equivalents increased to $9.243 million as of September 30, 2025, up from $1.187 million at year‑end, driven by equity raises and warrant exercises.

The balance sheet shifted to shareholders’ equity of $6.977 million from a deficit at December 31, 2024. During 2025, the company completed public offerings with aggregate gross proceeds of approximately $5.0 million in January and $6.0 million in September, plus additional gross proceeds from warrant exercises, including $1.78 million tied to September warrants. It also established an ATM program up to $13.17 million and has an effective S‑3 shelf up to $100 million.

Management disclosed “substantial doubt” about the company’s ability to continue as a going concern given ongoing losses and expected negative operating cash flows. Reverse share splits of 1‑for‑9 and 1‑for‑15 were effected in November 2024 and July 2025, respectively. Shares outstanding were 3,126,642 as of November 9, 2025.

Silexion Therapeutics Corp (SLXN) filed a resale registration covering up to 1,292,348 ordinary shares and up to 372 warrants for sale by selling securityholders. The company will not receive proceeds from these sales; it may receive up to $4.9 million only if holders exercise 344,063 registered warrants for cash.

The registered shares comprise up to 473,576 existing shares, up to 344,063 shares issuable upon warrant exercise, and up to 474,709 shares issuable upon conversion of a convertible promissory note (assuming a $3.44 per‑share conversion price as disclosed). Ordinary shares outstanding were 3,126,642 as of the date hereof. If all registered warrants are exercised for shares and the assumed full note conversion occurs, shares outstanding could reach up to 3,945,414.

SLXN ordinary shares and warrants trade on Nasdaq as “SLXN” and “SLXNW.” On October 29, 2025, the last reported prices were $3.44 per share and $0.04 per warrant. The filing states investing involves a high degree of risk; see the risk factors for details.

Silexion Therapeutics Corp is a Cayman Islands clinical-stage biotech focused on RNAi silencing of KRAS for KRAS G12D/V locally advanced pancreatic cancer. Their lead candidate, SIL204, is a second-generation siRNA delivered intratumorally plus subcutaneous systemic dosing alongside standard-of-care chemotherapy. The company completed a public offering on September 12, 2025 raising approximately $6.0 million gross and holds an At-The-Market sales agreement to offer up to $13.17 million of ordinary shares through H.C. Wainwright. As of June 30, 2025 pro forma cash was presented and pro forma shareholders’ equity increased after recent financings. Management plans toxicology studies in 2025 and regulatory submissions to support a planned Phase 2/3 randomized trial initiating in H1 2026.

Silexion Therapeutics Corp entered into an at-the-market offering agreement with H.C. Wainwright & Co., LLC and filed the agreement as an exhibit. The filing shows the company executed an arrangement to sell shares into the open market over time through the placement agent, providing a flexible means to raise capital as needed. The document includes an executed signature block by the Chief Executive Officer, indicating the agreement is authorized by management.

Silexion Therapeutics Corp. received a Nasdaq Compliance Letter confirming it has met the Nasdaq Capital Market's shareholder equity requirement and minimum $1.00 bid price requirement. The company completed financings that increased pro forma shareholders' equity by $10.3 million to approximately $9.41 million as of September 15, 2025. After a 1-for-15 reverse share split effected July 29, 2025, the closing price of the ordinary shares has been above $1.00. Nasdaq will monitor the company via a mandatory panel monitor through September 23, 2026, and a future equity deficiency during that period could lead to a delist determination and a new hearing opportunity.

Silexion Therapeutics Corp Schedule 13D/A reports that Moringa-related parties disclosed ownership totaling approximately 14.6% of the company's ordinary shares. The filing states Silexion issued 450,000 ordinary shares to Moringa Sponsor, LP on September 15, 2025, in conversion of $1.8 million of an outstanding promissory note, but the Reporting Persons expressly dispute the validity of that issuance and do not concede beneficial ownership of those shares. The cover-page totals combine 6,970 issued ordinary shares, 372 ordinary shares underlying warrants and the 450,000 shares the Reporting Persons contest. The Reporting Persons also reported a pro rata distribution on August 7, 2025 of certain shares and warrants to limited partners.

The reporting persons—Lind Global Fund III LP, Lind Global Partners III LLC and Jeff Easton—filed a Schedule 13G reporting beneficial ownership of 224,050 ordinary shares of Silexion Therapeutics Corp (CUSIP G1281K122), representing 9.9% of the class. The disclosed position consists of 106,250 ordinary shares and warrants (106,250 Series A-1 and 106,250 Series A-2) subject to conversion limits that cap aggregate beneficial ownership at 224,050 shares to prevent ownership above 9.99%. Lind Global Partners III LLC is the general partner of the fund and Jeff Easton is the managing member; each may be deemed to have sole voting and dispositive power over the reported shares. The filers certify the holdings were not acquired to change or influence control of the issuer.

Silexion Therapeutics Corp disclosed that three reporting persons—Intracoastal Capital, LLC, Mitchell P. Kopin and Daniel B. Asher—may each be deemed to beneficially own 244,771 ordinary shares, representing 9.99% of the class as of close of business on September 17, 2025. The filing explains these shares arise primarily from warrants issued under a Securities Purchase Agreement and notes multiple warrants include blocker provisions that limit exercise to prevent ownership above 9.99% (and 4.99% for one warrant). Voting and dispositive power over the 244,771 shares is reported as shared rather than sole.